CHIP Clonal Hematopoiesis Agent
The CHIP Clonal Hematopoiesis Agent provides comprehensive detection and risk stratification of clonal hematopoiesis of indeterminate potential (CHIP). It identifies clonal mutations in blood cells, assesses risk of progression to myeloid malignancy, and predicts cardiovascular disease risk, integrating with the CHIC machine learning framework for CBC-based screening.
When to Use This Skill
- When detecting CHIP mutations from blood sequencing data.
- For stratifying risk of progression to MDS/AML.
- To assess CHIP-associated cardiovascular disease risk.
- When filtering CHIP variants from tumor liquid biopsy.
- For population-level CHIP screening and research.
Core Capabilities
CHIP Detection: Identify clonal mutations with VAF >2%.
Risk Stratification: Predict myeloid malignancy progression risk.
CVD Risk Assessment: Estimate cardiovascular disease risk.
CCUS Classification: Distinguish CHIP from CCUS/MDS.
Clone Size Tracking: Monitor clonal evolution over time.
ctDNA Filtering: Remove CHIP from tumor ctDNA analysis.
CHIP-Associated Genes
| Gene |
Frequency |
Malignancy Risk |
CVD Risk |
| DNMT3A |
50% |
Moderate |
Elevated |
| TET2 |
20% |
Moderate |
Elevated (inflammatory) |
| ASXL1 |
10% |
High |
Moderate |
| JAK2 |
5% |
High (MPN) |
Elevated (thrombosis) |
| TP53 |
5% |
Very High |
Low |
| SF3B1 |
3% |
Moderate-High |
Low |
| SRSF2 |
3% |
High |
Low |
| PPM1D |
2% |
Moderate |
Therapy-related |
| CBL |
2% |
High |
Moderate |
| IDH1/2 |
2% |
Moderate-High |
Low |
Risk Categories
| Category |
Criteria |
Annual AML Risk |
| Low-Risk CHIP |
DNMT3A/TET2, VAF <10% |
<0.5% |
| Intermediate CHIP |
DNMT3A/TET2, VAF >10% |
0.5-1% |
| High-Risk CHIP |
ASXL1, TP53, splicing |
1-3% |
| CCUS |
CHIP + cytopenia |
3-10% |
| Pre-MDS |
High-risk mutations + dysplasia |
>10% |
Workflow
Input: Blood sequencing (WES/panel), CBC data, clinical history.
Variant Detection: Call somatic variants with VAF filtering.
CHIP Classification: Identify CHIP-defining mutations.
Risk Scoring: Calculate malignancy and CVD risk scores.
Longitudinal Analysis: Track clone dynamics if serial samples.
Clinical Integration: Generate management recommendations.
Output: CHIP status, risk scores, monitoring plan.
Example Usage
User: "Analyze this patient's blood sequencing for CHIP and calculate their risk of progression and cardiovascular events."
Agent Action:
python3 Skills/Hematology/CHIP_Clonal_Hematopoiesis_Agent/chip_analysis.py \
--variants blood_variants.vcf \
--cbc_data patient_cbc.csv \
--clinical_data patient_demographics.json \
--vaf_threshold 0.02 \
--age 65 \
--calculate_cvd_risk true \
--output chip_analysis/
CHRS Risk Score (Clonal Hematopoiesis Risk Score)
| Factor |
Points |
Notes |
| High-risk mutation |
+2 |
SRSF2, SF3B1, ZRSR2, IDH1/2, FLT3, RUNX1, JAK2 |
| Single DNMT3A mutation |
-1 |
Lower risk |
| ≥2 mutations |
+1 |
Increased burden |
| VAF ≥20% |
+1 |
Large clone |
| CCUS (vs CHIP) |
+2 |
Cytopenia present |
| RDW ≥15% |
+1 |
Blood count abnormality |
| MCV ≥100 fL |
+1 |
Macrocytosis |
| Age ≥65 |
+1 |
Age-related risk |
Output Components
| Output |
Description |
Format |
| CHIP Status |
Present/Absent, genes involved |
.json |
| Mutation Details |
VAF, gene, protein change |
.csv |
| Malignancy Risk |
5-year AML/MDS probability |
.json |
| CVD Risk |
Cardiovascular risk score |
.json |
| CHRS Score |
Clonal hematopoiesis risk score |
.json |
| Recommendations |
Clinical management |
.md |
| Monitoring Plan |
Follow-up schedule |
.json |
AI/ML Components
CHIC Framework:
- Machine learning from CBC indices
- Identifies high-risk CHIP without sequencing
- Reduces "number needed to sequence"
Risk Prediction:
- Cox proportional hazards for progression
- Random survival forests
- Deep learning survival models
CVD Risk Integration:
- Framingham score adjustment
- CHIP-specific hazard ratios
- Inflammatory biomarker integration
Cardiovascular Risk
| CHIP Gene |
CVD Hazard Ratio |
Mechanism |
| TET2 |
1.9 |
IL-6, inflammasome |
| DNMT3A |
1.7 |
Inflammation |
| JAK2 |
2.6 |
Thrombosis, platelet activation |
| ASXL1 |
2.0 |
Inflammation |
| Overall CHIP |
1.5-2.0 |
Multiple pathways |
Clinical Management Guidelines
| CHIP Category |
Monitoring |
Intervention |
| Low-risk |
Annual CBC |
None |
| Intermediate |
CBC q6 months |
CVD optimization |
| High-risk |
CBC q3-6 months, consider BMB |
Hematology referral |
| CCUS |
BMB, q3 month CBC |
Active surveillance |
Prerequisites
- Python 3.10+
- Variant callers (Mutect2, VarScan)
- ANNOVAR/VEP for annotation
- lifelines, scikit-survival
- CHIC model weights
Related Skills
- MPN_Progression_Monitor_Agent - MPN monitoring
- CHIC_ML_Framework_Agent - CBC-based screening
- MDS_Classification_Agent - MDS diagnosis
- Bone_Marrow_AI_Agent - Morphology analysis
CHIP vs ctDNA Filtering
| Feature |
CHIP |
Tumor ctDNA |
| VAF Stability |
Stable over time |
Changes with disease |
| Genes |
DNMT3A, TET2, ASXL1 |
Tumor drivers |
| Age Association |
Increases with age |
Independent |
| Multiple Samples |
Consistent |
Variable |
Special Considerations
- VAF Threshold: Use 2% for CHIP definition
- Germline Filtering: Exclude germline variants
- Age Context: Prevalence increases with age
- Therapy History: Consider treatment-related clones
- Serial Monitoring: Track clone dynamics
Population Prevalence
| Age Group |
CHIP Prevalence |
High-Risk CHIP |
| 40-49 |
~2% |
<0.5% |
| 50-59 |
~5% |
~1% |
| 60-69 |
~10% |
~2% |
| 70-79 |
~15% |
~4% |
| 80+ |
~20% |
~5% |
Therapeutic Implications
| Scenario |
CHIP Impact |
Consideration |
| CAR-T Therapy |
May affect outcomes |
Monitor clones |
| Stem Cell Transplant |
Donor CHIP matters |
Screen donors |
| Chemotherapy |
May expand clones |
Monitor post-treatment |
| Cardiovascular |
Increased risk |
Aggressive prevention |
Author
AI Group - Biomedical AI Platform
1---2name: chip-clonal-hematopoiesis-agent-23description: AI-powered clonal hematopoiesis of indeterminate potential (CHIP) detection, risk stratification, and cardiovascular/malignancy risk prediction using genomic and clinical data.4license: MIT5---67# CHIP Clonal Hematopoiesis Agent89The **CHIP Clonal Hematopoiesis Agent** provides comprehensive detection and risk stratification of clonal hematopoiesis of indeterminate potential (CHIP). It identifies clonal mutations in blood cells, assesses risk of progression to myeloid malignancy, and predicts cardiovascular disease risk, integrating with the CHIC machine learning framework for CBC-based screening.1011## When to Use This Skill1213* When detecting CHIP mutations from blood sequencing data.14* For stratifying risk of progression to MDS/AML.15* To assess CHIP-associated cardiovascular disease risk.16* When filtering CHIP variants from tumor liquid biopsy.17* For population-level CHIP screening and research.1819## Core Capabilities20211. **CHIP Detection**: Identify clonal mutations with VAF >2%.22232. **Risk Stratification**: Predict myeloid malignancy progression risk.24253. **CVD Risk Assessment**: Estimate cardiovascular disease risk.26274. **CCUS Classification**: Distinguish CHIP from CCUS/MDS.28295. **Clone Size Tracking**: Monitor clonal evolution over time.30316. **ctDNA Filtering**: Remove CHIP from tumor ctDNA analysis.3233## CHIP-Associated Genes3435| Gene | Frequency | Malignancy Risk | CVD Risk |36|------|-----------|-----------------|----------|37| DNMT3A | 50% | Moderate | Elevated |38| TET2 | 20% | Moderate | Elevated (inflammatory) |39| ASXL1 | 10% | High | Moderate |40| JAK2 | 5% | High (MPN) | Elevated (thrombosis) |41| TP53 | 5% | Very High | Low |42| SF3B1 | 3% | Moderate-High | Low |43| SRSF2 | 3% | High | Low |44| PPM1D | 2% | Moderate | Therapy-related |45| CBL | 2% | High | Moderate |46| IDH1/2 | 2% | Moderate-High | Low |4748## Risk Categories4950| Category | Criteria | Annual AML Risk |51|----------|----------|-----------------|52| Low-Risk CHIP | DNMT3A/TET2, VAF <10% | <0.5% |53| Intermediate CHIP | DNMT3A/TET2, VAF >10% | 0.5-1% |54| High-Risk CHIP | ASXL1, TP53, splicing | 1-3% |55| CCUS | CHIP + cytopenia | 3-10% |56| Pre-MDS | High-risk mutations + dysplasia | >10% |5758## Workflow59601. **Input**: Blood sequencing (WES/panel), CBC data, clinical history.61622. **Variant Detection**: Call somatic variants with VAF filtering.63643. **CHIP Classification**: Identify CHIP-defining mutations.65664. **Risk Scoring**: Calculate malignancy and CVD risk scores.67685. **Longitudinal Analysis**: Track clone dynamics if serial samples.69706. **Clinical Integration**: Generate management recommendations.71727. **Output**: CHIP status, risk scores, monitoring plan.7374## Example Usage7576**User**: "Analyze this patient's blood sequencing for CHIP and calculate their risk of progression and cardiovascular events."7778**Agent Action**:79```bash80python3 Skills/Hematology/CHIP_Clonal_Hematopoiesis_Agent/chip_analysis.py \81 --variants blood_variants.vcf \82 --cbc_data patient_cbc.csv \83 --clinical_data patient_demographics.json \84 --vaf_threshold 0.02 \85 --age 65 \86 --calculate_cvd_risk true \87 --output chip_analysis/88```8990## CHRS Risk Score (Clonal Hematopoiesis Risk Score)9192| Factor | Points | Notes |93|--------|--------|-------|94| High-risk mutation | +2 | SRSF2, SF3B1, ZRSR2, IDH1/2, FLT3, RUNX1, JAK2 |95| Single DNMT3A mutation | -1 | Lower risk |96| ≥2 mutations | +1 | Increased burden |97| VAF ≥20% | +1 | Large clone |98| CCUS (vs CHIP) | +2 | Cytopenia present |99| RDW ≥15% | +1 | Blood count abnormality |100| MCV ≥100 fL | +1 | Macrocytosis |101| Age ≥65 | +1 | Age-related risk |102103## Output Components104105| Output | Description | Format |106|--------|-------------|--------|107| CHIP Status | Present/Absent, genes involved | .json |108| Mutation Details | VAF, gene, protein change | .csv |109| Malignancy Risk | 5-year AML/MDS probability | .json |110| CVD Risk | Cardiovascular risk score | .json |111| CHRS Score | Clonal hematopoiesis risk score | .json |112| Recommendations | Clinical management | .md |113| Monitoring Plan | Follow-up schedule | .json |114115## AI/ML Components116117**CHIC Framework**:118- Machine learning from CBC indices119- Identifies high-risk CHIP without sequencing120- Reduces "number needed to sequence"121122**Risk Prediction**:123- Cox proportional hazards for progression124- Random survival forests125- Deep learning survival models126127**CVD Risk Integration**:128- Framingham score adjustment129- CHIP-specific hazard ratios130- Inflammatory biomarker integration131132## Cardiovascular Risk133134| CHIP Gene | CVD Hazard Ratio | Mechanism |135|-----------|------------------|-----------|136| TET2 | 1.9 | IL-6, inflammasome |137| DNMT3A | 1.7 | Inflammation |138| JAK2 | 2.6 | Thrombosis, platelet activation |139| ASXL1 | 2.0 | Inflammation |140| Overall CHIP | 1.5-2.0 | Multiple pathways |141142## Clinical Management Guidelines143144| CHIP Category | Monitoring | Intervention |145|---------------|------------|--------------|146| Low-risk | Annual CBC | None |147| Intermediate | CBC q6 months | CVD optimization |148| High-risk | CBC q3-6 months, consider BMB | Hematology referral |149| CCUS | BMB, q3 month CBC | Active surveillance |150151## Prerequisites152153* Python 3.10+154* Variant callers (Mutect2, VarScan)155* ANNOVAR/VEP for annotation156* lifelines, scikit-survival157* CHIC model weights158159## Related Skills160161* MPN_Progression_Monitor_Agent - MPN monitoring162* CHIC_ML_Framework_Agent - CBC-based screening163* MDS_Classification_Agent - MDS diagnosis164* Bone_Marrow_AI_Agent - Morphology analysis165166## CHIP vs ctDNA Filtering167168| Feature | CHIP | Tumor ctDNA |169|---------|------|-------------|170| VAF Stability | Stable over time | Changes with disease |171| Genes | DNMT3A, TET2, ASXL1 | Tumor drivers |172| Age Association | Increases with age | Independent |173| Multiple Samples | Consistent | Variable |174175## Special Considerations1761771. **VAF Threshold**: Use 2% for CHIP definition1782. **Germline Filtering**: Exclude germline variants1793. **Age Context**: Prevalence increases with age1804. **Therapy History**: Consider treatment-related clones1815. **Serial Monitoring**: Track clone dynamics182183## Population Prevalence184185| Age Group | CHIP Prevalence | High-Risk CHIP |186|-----------|-----------------|----------------|187| 40-49 | ~2% | <0.5% |188| 50-59 | ~5% | ~1% |189| 60-69 | ~10% | ~2% |190| 70-79 | ~15% | ~4% |191| 80+ | ~20% | ~5% |192193## Therapeutic Implications194195| Scenario | CHIP Impact | Consideration |196|----------|-------------|---------------|197| CAR-T Therapy | May affect outcomes | Monitor clones |198| Stem Cell Transplant | Donor CHIP matters | Screen donors |199| Chemotherapy | May expand clones | Monitor post-treatment |200| Cardiovascular | Increased risk | Aggressive prevention |201202## Author203204AI Group - Biomedical AI Platform
majiayu000